ClinicalTrials.gg
CompletedNCT06948032Updated Apr 28, 2025

Study of BLU-808 in Healthy Adult Participants

A Phase 1 interventional study of BLU-808 and Placebo in Healthy Participants, sponsored by Blueprint Medicines Corporation. Completed at 1 site in United States. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-28.

Sponsored by Blueprint Medicines Corporation (part of Sanofi) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 9 months ago, and no results have been posted to the registry.
  • Registered 8 months after the study started (first participant enrolled Aug 2024, registered Apr 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Study summary

This is a 3-part study. Parts 1 and 2 are randomized, double-blind, placebo-controlled investigations of single ascending doses (SAD) (Part 1) and multiple ascending doses (MAD) (Part 2) of orally administered BLU-808 in healthy adult participants. Part 2 will also include an evaluation of the effect of multiple doses of BLU-808 on the single-dose pharmacokinetics (PK) of midazolam. Part 3 is an open-label, 2-sequence, 2-period, food effect (FE) study in healthy adult participants.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Blueprint Medicines Corporation is the lead sponsor of 32 studies on the registry; 6 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 3 (21%) have results posted.

First submitted before Blueprint Medicines Corporation became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on subject self-reporting.
  • Medically healthy with no medical history, physical examination, clinical laboratory profiles, or vital signs, as deemed by the Principal Investigator (PI) or designee.
  • No clinically significant cardiac history as judged by the PI or designee at the screening visit and check-in.

Key Exclusion Criteria:

  • Participant is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  • Participant has history or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI, designee, or Sponsor.
  • Participant has history or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.
  • Participant has positive results at the screening visit for (HIV), surface antigen (HBsAg), or virus (HCV).
  • Participant has been on a diet incompatible with the on-study diet (that is, unusual meal habits and special diet requirements or unwillingness to eat the food provided in the trial), in the opinion of the PI or designee, within the 30 days prior to the first dosing and throughout the study.
  • Participant has participated in another clinical study within 30 days prior to the first dosing. The 30-day window will be derived from the date of the last dosing in the previous study to the first dosing of the current study.
  • Participant has positive coronavirus disease 2019 (COVID-19) results at first check-in.

Note: Other protocol-specified inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Part 1: BLU-808

    BLU-808 will be administered orally.

    Drug: BLU-808

  • Placebo comparator
    Part 1: Placebo

    Matching placebo for BLU-808 will be administered orally.

    Drug: Placebo

  • Experimental
    Part 2: BLU-808

    BLU-808 will be administered orally.

    Drug: BLU-808

  • Placebo comparator
    Part 2: Placebo

    Matching placebo for BLU-808 will be administered orally.

    Drug: Placebo

  • Experimental
    Part 2: Midazolam Alone Followed by BLU-808 and Midazolam

    Participants will receive oral midazolam in Period 1. Participants will then receive oral BLU-808 with midazolam in period 2.

    Drug: BLU-808 · Drug: Midazolam

  • Placebo comparator
    Part 2: Midazolam Alone Followed by BLU-808 Matching Placebo and Midazolam

    Participants will receive oral midazolam in Period 1. Participants will then receive oral matching placebo for BLU-808 with midazolam in period 2.

    Drug: Placebo · Drug: Midazolam

  • Experimental
    Part 3: BLU-808 (Treatment D, E)

    BLU-808 will be administered orally.

    Drug: BLU-808

  • Experimental
    Part 3: BLU-808 (Treatment E, D)

    BLU-808 will be administered orally.

    Drug: BLU-808

Interventions

  • BLU-808 will be administered per schedule specified in the arm description.

  • DrugPlacebo

    BLU-808 matching placebo will be administered per schedule specified in the arm description.

  • Midazolam will be administered per schedule specified in the arm description.

06

What researchers measure

Primary outcomes

  1. Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to Day 20

  2. Part 2: Number of Participants With TEAEs

    Time frame: Up to Day 50

  3. Part 3: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Non-zero Concentration (AUC0-t)

    Time frame: Up to Day 6

  4. Part 3: Maximum Observed Plasma Concentration (Cmax)

    Time frame: Up to Day 6

Secondary outcomes

  1. Part 1: AUC0-t

    Time frame: Up to Day 6

  2. Part 1: Cmax

    Time frame: Up to Day 6

  3. Part 1: Terminal Elimination Half-life (t1/2)

    Time frame: Up to Day 6

  4. Part 1: Change From Baseline in QTc (Corrected Value of the Interval Between the Q and T Waves on the Electrocardiogram Tracing)

    Time frame: Up to Day 6

  5. Parts 1 and 2: Change From Baseline in Serum Tryptase Concentrations

    Time frame: Up to Day 6

  6. Part 2: AUC0-t

    Time frame: Up to Day 14

  7. Part 2: Cmax

    Time frame: Up to Day 14

  8. Part 2: t1/2

    Time frame: Up to Day 19

  9. Part 3: Number of Participants With TEAEs

    Time frame: Up to Day 26

07

Study locations

1 site
  • Celerion, Inc.
    Lincoln, Nebraska 68502, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Jan 2025, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2025
First posted
Apr 28, 2025
StartActual
Aug 7, 2024
Primary completionActual
Jan 21, 2025
CompletionActual
Jan 21, 2025
Last update
Apr 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06948032
Responsible party
Sponsor
First posted
Apr 28, 2025
Start date
Aug 7, 2024
Primary completion
Jan 21, 2025
Completion
Jan 21, 2025
Last update
Apr 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: BLU-808 · Midazolam

Start the discussion